Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyEvolving Management of Patients with Double-Hit Lymphoma

Double-hit lymphoma presents as both aggressive, systematic disease with extra-nodal involvement and, apparently, as low-stage, less clinically aggressive disease. Since R-CHOP is much less effective in double-hit lymphoma, options such as CAR-T as well as novel drugs targeting cell-surface markers are being investigated. This interview with Dr. Ann S. LaCasce of Dana Farber summarizes current understanding and approaches to double-hit lymphoma.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form